LifeMD (LFMD)
(Delayed Data from NSDQ)
$4.91 USD
-0.37 (-7.01%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.91 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.91 USD
-0.37 (-7.01%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.91 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth D Momentum B VGM
Zacks News
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD (LFMD) delivered earnings and revenue surprises of -46.15% and 4.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 14.29% and 10.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 26.67% and 1.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 88.89% and 2.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Life Time Group Holdings, Inc. (LTH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 22.22% and 0.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 4.78% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Upgraded to Buy: Here's Why
by Zacks Equity Research
LifeMD, Inc. (LFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LifeMD, Inc. (LFMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 3.85% and 6.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 25.64% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -150% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc are highlighted in this Industry Outlook article.
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc are highlighted in this industry outlook article.
3 Medical Services Stocks to Buy Despite Near-Term Industry Woes
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. AMN, AMEH and LFMD are set to gain the most. However, falling healthcare spending may disrupt the trend.
LifeMD, Inc. (LFMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 26.53% and 1.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 26th
by Zacks Equity Research
FSLY, GNSS, LFMD, NUAN, and QUOT have been added to the Zacks Rank #5 (Strong Sell) List on August 26, 2021
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of -13.33% and 3.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LifeMD, Inc. (LFMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
LifeMD, Inc. (LFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LifeMD, Inc. (LFMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 13.64% and -0.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About LifeMD (LFMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to LifeMD (LFMD) stock based on the movements in the options market lately.
Analysts Estimate LifeMD, Inc. (LFMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LifeMD, Inc. (LFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.